Durata Therapeutics Inc (DRTX)

24.16
0.41 1.73
Prev Close 23.75
Open 23.82
Day Low/High 23.80 / 24.17
52 Wk Low/High 9.94 / 24.33
Volume 1.08M
Avg Volume 658.30K
Exchange
Shares Outstanding 26.79M
Market Cap 647.33M
EPS -2.57
Div & Yield N.A. (N.A)

Latest News

Short Interest Decreases By 79% For DRTX

Short Interest Decreases By 79% For DRTX

The most recent short interest data has been released by the NASDAQ for the 10/15/2014 settlement date, which shows a 3,015,240 share decrease in total short interest for Durata Therapeutics Inc , to 797,665, a decrease of 79.08% since 09/30/2014. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation Of Durata Therapeutics, Inc. In Connection With The Sale Of The Company

SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation Of Durata Therapeutics, Inc. In Connection With The Sale Of The Company

Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Durata Therapeutics, Inc.

DURATA SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces The Investigation Of Durata Therapeutics Inc. (DRTX) Over The Proposed Sale Of The Company To Actavis Plc (ACT)

DURATA SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces The Investigation Of Durata Therapeutics Inc. (DRTX) Over The Proposed Sale Of The Company To Actavis Plc (ACT)

Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Durata Therapeutics Inc. (DRTX)

SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Durata Therapeutics, Inc. And Encourages Investors To Contact The Firm For Additional Information

SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Durata Therapeutics, Inc. And Encourages Investors To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of...

Durata Therapeutics Presents New Data For DALVANCE(TM) At IDWeek 2014(TM)

Durata Therapeutics Presents New Data For DALVANCE(TM) At IDWeek 2014(TM)

Newly Released Clinical and Pre-Clinical Analyses, Including Pharmacokinetics of Dalbavancin in Bone and Associated Tissues in Patients Undergoing Orthopedic Surgical Procedures

DURATA SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces The Investigation Of Durata Therapeutics Inc. (DRTX) Over The Proposed Sale Of The Company To Actavis Plc (ACT)

DURATA SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces The Investigation Of Durata Therapeutics Inc. (DRTX) Over The Proposed Sale Of The Company To Actavis Plc (ACT)

Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Durata Therapeutics Inc.

INVESTOR ALERT: The Law Offices Of Vincent Wong Investigates The Board Of Directors Of Durata Therapeutics Inc. Regarding The Fairness Of The Sale Of The Company To Actavis

INVESTOR ALERT: The Law Offices Of Vincent Wong Investigates The Board Of Directors Of Durata Therapeutics Inc. Regarding The Fairness Of The Sale Of The Company To Actavis

The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Durata Therapeutics Inc.

SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Durata Therapeutics, Inc. And Encourages Investors To Contact The Firm For Additional Information

SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Durata Therapeutics, Inc. And Encourages Investors To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of...

Market News: Advanced Technologies, Durata Therapeutics, Unilife

Market News: Advanced Technologies, Durata Therapeutics, Unilife

Investors were "anxious to see how company managements comment on the strong U.S. dollar and overseas revenue," according to Jim Russell of U.S. Bank Wealth ManagementThe stock markets in the Unit...

Glancy Binkow & Goldberg LLP Is Investigating Durata Therapeutics, Inc. Board Of Directors

Glancy Binkow & Goldberg LLP Is Investigating Durata Therapeutics, Inc. Board Of Directors

Glancy Binkow & Goldberg LLP is investigating potential claims against the Board of Directors of Durata Therapeutics, Inc.

DURATA THERAPEUTICS SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Acquisition By Actavis

DURATA THERAPEUTICS SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Acquisition By Actavis

Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Durata...

Why Durata Therapeutics (DRTX) Stock Hit a One-Year High Today

Why Durata Therapeutics (DRTX) Stock Hit a One-Year High Today

Shares of Durata Therapeutics (DRTX) soared to a 52-week high on Monday after Actavis (ACT) agreed to purchase the pharmaceutical company for approximately $675 million.

Actavis To Acquire Durata Therapeutics, Inc.

Actavis To Acquire Durata Therapeutics, Inc.

- Lead Product DALVANCE™ a Novel Antibiotic for Unmet Medical Need in Hospital and Outpatient Settings -

Short Interest Moves 12.2% Higher For DRTX

Short Interest Moves 12.2% Higher For DRTX

The most recent short interest data has been released by the NASDAQ for the 08/29/2014 settlement date, which shows a 362,858 share increase in total short interest for Durata Therapeutics Inc , to 3,347,269, an increase of 12.16% since 08/15/2014. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.